After decades of steady increases, the rise in sexually transmitted infections (STIs) across the United States may be beginning to slow, according to the latest data released by the Centers for Disease Control and Prevention. Although more than 2.4 million cases were reported in 2023, the numbers reveal encouraging, though preliminary, signs that prevention efforts and new diagnostic tools are starting to have an impact. This shift comes after years of concern over escalating rates of gonorrhea, syphilis, and chlamydia, which public health officials have linked to factors like reduced access to healthcare, pandemic-related disruptions, and changing sexual behaviors.
The most notable improvement is a 7% decline in gonorrhea cases compared to 2022, bringing the total below pre-pandemic levels seen in 2019. This marks the second consecutive year of decreases for this common STI. But, the overall picture remains complex. While overall syphilis cases still increased – albeit by a modest 1% – a deeper look reveals a significant turning point in the fight against the most dangerous forms of the infection.
A Shift in the Syphilis Epidemic
Cases of primary and secondary syphilis, the stages when the infection is most contagious, fell by 10% in 2023 – the first substantial decline in over two decades. This decline was particularly pronounced among gay and bisexual men, with a 13% decrease, the first since the CDC began tracking trends within this population in the mid-2000s. This is a critical development, as these stages of syphilis can lead to severe health complications if left untreated, including neurological damage, cardiovascular problems, and even death.
Perhaps the most concerning aspect of the STI epidemic in recent years has been the dramatic surge in congenital syphilis – syphilis passed from a pregnant person to their baby. While increases are still occurring, the rate of increase appears to be slowing. Nationally, congenital syphilis cases rose by 3% in 2023, a significant drop from the 30% annual increases observed in prior years. This slowing trend is attributed to increased screening of pregnant individuals and more aggressive treatment protocols, but continued vigilance is crucial to protect newborns from this preventable infection.
New Tools and Targeted Interventions
The recent positive trends coincide with the rollout of several new prevention and diagnostic tools. The CDC has issued guidelines for doxycycline post-exposure prophylaxis (doxy PEP), a strategy where a single dose of the antibiotic doxycycline is taken after unprotected sex to prevent bacterial STIs like gonorrhea, chlamydia, and syphilis. Doxy PEP is currently recommended for certain populations at high risk, and research is ongoing to determine its potential benefits for a wider range of individuals.
the Food and Drug Administration (FDA) has recently authorized at-home tests for syphilis, gonorrhea, and chlamydia, increasing access to testing and allowing individuals to get tested in the privacy of their own homes. These self-tests are expected to play a crucial role in early detection and treatment. A nationally coordinated response to the U.S. Syphilis epidemic is being spearheaded by the National Syphilis and Congenital Syphilis Syndemic Task Force, focusing on prevention, diagnosis, and treatment efforts.
Addressing Health Disparities
Despite these encouraging signs, significant disparities persist. American Indian/Alaska Native, Black/African American, and Hispanic/Latino communities, as well as gay and bisexual men, continue to be disproportionately affected by STIs. These inequities are rooted in deeply entrenched social and economic factors, including poverty, lack of health insurance, limited access to healthcare, and stigma. Federal efforts, such as those outlined by the Department of Health and Human Services, are underway to address these disparities, but sustained investment and community-level action are essential.
Looking Ahead
“I see a glimmer of hope amidst millions of STIs,” says Jonathan Mermin, M.D., M.P.H., Director of CDC’s National Center for HIV, Viral Hepatitis, STD, and TB Prevention. “After nearly two decades of STI increases, the tide is turning. We must make the most of this moment—let’s further this momentum with creative innovation and further investment in STI prevention.”
Experts emphasize that sustained efforts are needed to build on this momentum. Prioritizing STI prevention at all levels of government, developing new and more effective prevention strategies, investing in robust public health infrastructure, and expanding access to testing and treatment – particularly in underserved communities – are all critical steps. Delivering STI services in non-traditional settings, such as emergency departments, could also significantly improve access to care.
The CDC plans to release updated STI surveillance data in late 2024, providing a more comprehensive picture of trends and informing future prevention efforts. Continued monitoring and research will be essential to understand the long-term impact of these interventions and to address the ongoing challenges posed by STIs in the United States.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What do you think about these new trends in STI rates? Share your thoughts in the comments below, and please share this article with your network to raise awareness about this important public health issue.
